Free Trial

Amedisys (AMED) Competitors

Amedisys logo
$97.46 -0.01 (-0.01%)
Closing price 04:00 PM Eastern
Extended Trading
$97.46 0.00 (-0.01%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMED vs. DVA, CHE, CRVL, MD, AMN, CCRN, LH, DGX, EHC, and ELAN

Should you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Labcorp (LH), Quest Diagnostics (DGX), Encompass Health (EHC), and Elanco Animal Health (ELAN).

Amedisys vs. Its Competitors

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Amedisys currently has a consensus target price of $100.75, suggesting a potential upside of 3.38%. DaVita has a consensus target price of $164.50, suggesting a potential upside of 16.56%. Given DaVita's higher possible upside, analysts plainly believe DaVita is more favorable than Amedisys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedisys
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25
DaVita
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

DaVita has a net margin of 6.63% compared to Amedisys' net margin of 3.79%. DaVita's return on equity of 176.11% beat Amedisys' return on equity.

Company Net Margins Return on Equity Return on Assets
Amedisys3.79% 12.52% 7.01%
DaVita 6.63%176.11%4.66%

94.4% of Amedisys shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 2.1% of Amedisys shares are held by company insiders. Comparatively, 2.0% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$2.35B1.36$43.23M$2.7135.96
DaVita$12.82B0.83$936.34M$10.0913.99

In the previous week, DaVita had 8 more articles in the media than Amedisys. MarketBeat recorded 13 mentions for DaVita and 5 mentions for Amedisys. DaVita's average media sentiment score of 1.18 beat Amedisys' score of 1.12 indicating that DaVita is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amedisys
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DaVita
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amedisys has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Summary

DaVita beats Amedisys on 9 of the 15 factors compared between the two stocks.

Get Amedisys News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMED vs. The Competition

MetricAmedisysMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.20B$3.80B$5.54B$9.41B
Dividend YieldN/A1.35%3.75%4.03%
P/E Ratio35.9622.2221.0120.09
Price / Sales1.36117.32433.8199.01
Price / Cash15.6422.6336.1658.27
Price / Book2.704.308.125.65
Net Income$43.23M$189.47M$3.25B$257.91M
7 Day Performance0.29%0.00%0.97%2.09%
1 Month Performance-0.44%-5.71%7.36%11.13%
1 Year Performance-0.28%-0.92%31.31%18.40%

Amedisys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMED
Amedisys
2.8973 of 5 stars
$97.46
0.0%
$100.75
+3.4%
-0.3%$3.20B$2.35B35.9619,000News Coverage
Positive News
Upcoming Earnings
DVA
DaVita
4.5028 of 5 stars
$143.43
+0.6%
$164.50
+14.7%
+2.6%$10.83B$12.82B14.2176,000Positive News
CHE
Chemed
4.9835 of 5 stars
$464.42
+1.0%
$645.00
+38.9%
-16.6%$6.79B$2.49B22.6215,695
CRVL
CorVel
0.9816 of 5 stars
$97.99
+0.2%
N/A+2.1%$5.04B$895.59M53.355,075News Coverage
Positive News
MD
Pediatrix Medical Group
3.0072 of 5 stars
$13.15
+0.2%
$16.67
+26.8%
+64.7%$1.13B$1.98B-13.014,305Positive News
AMN
AMN Healthcare Services
4.3446 of 5 stars
$20.72
-2.1%
$32.08
+54.8%
-64.4%$793.27M$2.85B-4.792,968News Coverage
Analyst Revision
CCRN
Cross Country Healthcare
3.6127 of 5 stars
$12.08
+0.1%
$17.93
+48.4%
-18.6%$396.02M$1.26B-22.798,205News Coverage
LH
Labcorp
4.6133 of 5 stars
$249.77
+0.1%
$276.38
+10.7%
+14.5%$20.91B$13.01B28.8770,000Upcoming Earnings
Analyst Forecast
DGX
Quest Diagnostics
4.9476 of 5 stars
$168.34
+0.1%
$185.73
+10.3%
+13.3%$18.79B$9.87B21.2856,000Upcoming Earnings
Analyst Forecast
EHC
Encompass Health
4.9297 of 5 stars
$119.64
+1.0%
$131.50
+9.9%
+27.0%$12.06B$5.37B24.7240,000News Coverage
ELAN
Elanco Animal Health
1.8068 of 5 stars
$14.88
-0.2%
$15.33
+3.1%
+14.6%$7.39B$4.44B20.109,000Analyst Upgrade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:AMED) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners